贝伐单抗在肺癌应中的全程管理.pptVIP

2-year OS rate was similar between arms (24.4 vs 21.2 %), however 2-year OS rate for patients who received 维持治疗 was 34.5 vs 26.5 % -Pem+Cb+Bev followed by Pem+ Bev had significantly more study drug-related grade 3/4 anemia, thrombocytopenia, and fatigue compared with Pac+Cb+Bev -Pac+Cb +Bev followed by Bev had significantly more study drug–related grade 3/4 neutropenia, febrile neutropenia, sensory neuropathy, and complete alopecia (grade 2). * * * Research Funding – Yes (Roche, Lilly) (MO22089; NC Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 pa